Connect Biopharma to Present at the Jefferies Virtual London Healthcare Conference on November 17, 2020

SAN DIEGO and TAICANG,SUZHOU,China,Nov. 9,2020 -- Connect Biopharma,a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune and inflammatory diseases,today announced that Zheng Wei,Co-Founder & CEO of Connect Biopharma,will present at the Jefferies Virtual London Healthcare Conference on Tuesday,November 17,2020 at 1:10 pm EST / 6:10 pm GMT.

About Connect Biopharma

Connect Biopharma is a U.S.- andChina-based clinical-stage biopharmaceutical company,focused on the discovery and development of next-generation immune modulators to be used in the treatment of serious autoimmune and inflammatory diseases.Leveragingour expertise in the biology of T cell modulationand our proprietary Immune Modulation Technology Platform,a high-throughput screening platform that rapidly and efficiently identifies molecules that target clinically validated disease pathways,we are a company passionate about developing innovative medicines and improving the lives of those suffering from these chronic and debilitating diseases worldwide.

In addition toourlead drug candidates,CBP-201 and CBP-307,wearealso advancing three preclinical programs,comprising two small molecule candidates (CBP-174 and CBP-312) and one antibody targeting IL-33 (CBP-233) as treatments for various serious inflammatory conditions. Wehold all global rights toourproprietary pipeline and discovery technologies. For additional information about Connect Biopharma,please visitour website at www.connectbiopharm.com

IR/PR CONTACTS:

Lazar FINN Partners

David Carey(IR)

T: +1-(212) 867-1768

david.carey@finnpartners.com

Erich Sandoval (Media)

+1-(646) 871-8482 or +1-(917) 497-2867

erich.sandoval@finnpartners.com

Corporate Contacts:

info@connectpharm.com